Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.

Bulletin of the World Health Organization - 1 Jan 1997

Murphy B R, Collins P L

Abstract excerpt

A Joint WHO/National Institute of Allergy and Infectious Diseases (NIAID) meeting on the current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development was held in Bethesda, MD, from 30 September to 1 October 1996. The meeting summarized the worldwide impact of RSV and PIV3; presented the current status of development of RSV and PIV3 vaccines; and examined the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA, Complementary
Share to DNA, Recombinant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Viral

Share to Infant

Share to Infant, Newborn

Share to Mutation

Share to United States

Share to Vaccines, Attenuated

Source

Open in PubMed Open full text

Identifiers

PMID: 9342889
PMCID: PMC2486968

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.PMID 9342889Read ↗

Challenges in developing a pediatric RSV vaccineSemantic proximity Read ↗

Mucosal Immunization of Rhesus Monkeys against Respiratory Syncytial Virus Subgroups A and B and Human Parainfluenza Virus Type 3 by Using a Live cDNA-Derived Vaccine Based on a Host Range-Attenuated Bovine Parainfluenza Virus Type 3 Vector BackboneSemantic proximity Read ↗

Current status of vaccines for parainfluenza virus infections.Semantic proximity Read ↗

Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine CandidateSemantic proximity Read ↗

A cDNA Clone-Launched Platform for High-Yield Production of Inactivated Zika VaccineSemantic proximity Read ↗

Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in ChildrenSemantic proximity Read ↗

New mucosal bivalent live-attenuated vaccine is protective against Human Metapneumovirus and Respiratory Syncytial VirusSemantic proximity Read ↗

Evaluation of the Replication and Immunogenicity of Recombinant Human Parainfluenza Virus Type 3 Vectors Expressing up to Three Foreign GlycoproteinsSemantic proximity Read ↗

A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.Semantic proximity Read ↗

PIV-3 vaccine National Institutes of Health/Aviron.Semantic proximity Read ↗

Review of Poultry Recombinant Vector VaccinesSemantic proximity Read ↗

Recombinant Bovine/Human Parainfluenza Virus Type 3 (B/HPIV3) Expressing the Respiratory Syncytial Virus (RSV) G and F Proteins Can Be Used To Achieve Simultaneous Mucosal Immunization against RSV and HPIV3Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.